Qingdao Baheal Medical, Inc. (301015.SZ) Latest Company News

Oct 20, 2026, 08:58 UTC
Beijing Baiyang Zhihe Medical Achievement Transformation Service Co., Ltd. filed a service-contract lawsuit against Yangzhou Yiyang Pharmaceutical Co., Ltd., and the Beijing No. 1 Intermediate People's Court accepted the case; it has not yet gone to trial.
Source:
- finance.sina.cn
Oct 15, 2026, 07:49 UTC
Baiyang Pharmaceutical Group completed the release of a pledge on 6,771,768 shares of Baiyang Pharmaceutical, equal to 1.92% of the company’s total shares and 1.29% of the group’s holdings, with Daye Trust as pledgee.
Source:
- finance.sina.cn
Sep 22, 2026, 09:56 UTC
Baheal Pharmaceutical's wholly owned subsidiary Baheal Health Industry International Trading plans to exercise warrants to subscribe for 15.2144 million E-1 series preferred shares of Zap Medical at $0.723 per share, for a total investment of about $11 million, raising its indirect stake in Zap Medical to 20.86%.
Source:
- finance.sina.cn
Sep 22, 2026, 09:27 UTC
Baheal Pharmaceutical announced it plans to jointly establish the Mentougou Baheal Phase III Pharmaceutical Industry Investment Fund with Baheal Zhongxin, Jingxi Industry Guidance Fund, and Gongqingcheng Wanheng, with a total committed size of 400 million yuan, in which Baheal Pharmaceutical as a limited partner will contribute 156 million yuan of its own funds, accounting for 39%.
Source:
- finance.sina.cn
Aug 28, 2026, 12:01 UTC
Baheal Pharmaceutical plans to invest 40 million yuan in Tianjin Jikun Pharmaceutical Technology Co., Ltd., increasing its stake to 25.44%.
Source:
- finance.sina.cn
Aug 28, 2026, 10:58 UTC
Baiyang Pharmaceutical announced its 2026 first-half results: revenue of 3.56 billion yuan, down 5.11% year-on-year; net profit attributable to shareholders of 225 million yuan, up 37.72% year-on-year.
Source:
- finance.sina.cn
Aug 28, 2026, 10:58 UTC
Baiyang Pharmaceutical announced plans to publicly issue H shares and list on the Main Board of the Hong Kong Stock Exchange.
Source:
- finance.sina.cn
Jul 7, 2026, 00:42 UTC
Baheal Medical's first third-party ZAP-X radiosurgery center at Peking University International Hospital completed its first clinical treatment, marking the formal entry of ZAP-X into large-scale clinical application.
Source:
- finance.sina.cn

301015.SZ

Beijing Baiyang Zhihe Medical Achievement Transformation Service Co., Ltd. filed a service-contract lawsuit against Yangzhou Yiyang Pharmaceutical Co., Ltd., and the Beijing No. 1 Intermediate People's Court accepted the case; it has not yet gone to trial.

Baiyang Pharmaceutical Group completed the release of a pledge on 6,771,768 shares of Baiyang Pharmaceutical, equal to 1.92% of the company’s total shares and 1.29% of the group’s holdings, with Daye Trust as pledgee.

Baheal Pharmaceutical plans to invest 40 million yuan in Tianjin Jikun Pharmaceutical Technology Co., Ltd., increasing its stake to 25.44%.

Baiyang Pharmaceutical announced its 2026 first-half results: revenue of 3.56 billion yuan, down 5.11% year-on-year; net profit attributable to shareholders of 225 million yuan, up 37.72% year-on-year.

Baiyang Pharmaceutical announced plans to publicly issue H shares and list on the Main Board of the Hong Kong Stock Exchange.

Baheal Medical's first third-party ZAP-X radiosurgery center at Peking University International Hospital completed its first clinical treatment, marking the formal entry of ZAP-X into large-scale clinical application.